Reaction
Trichorrhexis reporting signals
As of the last recalculation, Trichorrhexis appears in 2,756 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is BIMATOPROST (PRR 81.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bimatoprost | 281 | 81.9 | 82.7 |
| Minoxidil | 207 | 37.5 | 37.7 |
| Ketoconazole | 40 | 17.7 | 17.7 |
| Biotin | 70 | 17.4 | 17.4 |
| Minoxidil Foam 5% (Womens) | 58 | 13.5 | 13.6 |
| Ketoconazole Cream, 2% | 25 | 12.8 | 12.8 |
| Ketoconazole Foam | 24 | 12.4 | 12.4 |
| Thyroid, Porcine | 15 | 10.7 | 10.7 |
| Carboxymethylcellulose Sodium | 11 | 8.9 | 8.9 |
| Liothyronine Sodium | 9 | 7.8 | 7.8 |
| Anastrozole Tablets | 19 | 6.7 | 6.7 |
| Fremanezumab-Vfrm | 9 | 5.9 | 5.9 |
| Anastrozole | 28 | 5.8 | 5.8 |
| Teriflunomide | 31 | 5.2 | 5.2 |
| Clobetasol Propionate Ointment Usp, 0.05% | 7 | 5.1 | 5.1 |
| Clobetasol Propionate | 7 | 5.1 | 5.1 |
| Ribociclib | 21 | 5.1 | 5.1 |
| Abemaciclib | 12 | 4.5 | 4.6 |
| Letrozole Tablets | 26 | 4.1 | 4.1 |
| Palbociclib | 51 | 4.1 | 4.1 |
| Erlotinib | 5 | 3.9 | 3.9 |
| Lanreotide Acetate | 4 | 3.9 | 3.9 |
| Avapritinib | 6 | 3.7 | 3.7 |
| Erlotinib Hydrochloride | 6 | 3.6 | 3.6 |
| Erenumab-Aooe | 26 | 3.6 | 3.6 |
| Ocrelizumab | 29 | 3.6 | 3.6 |
| Abaloparatide | 13 | 3.3 | 3.3 |
| Galcanezumab-Gnlm | 13 | 3.1 | 3.1 |
| Osimertinib | 13 | 3.1 | 3.1 |
| Voxelotor | 8 | 2.7 | 2.7 |
| Alpelisib | 3 | 2.6 | 2.6 |
| Siponimod | 3 | 2.5 | 2.5 |
| Oral Semaglutide | 23 | 2.4 | 2.4 |
| Dimethyl Fumarate | 37 | 2.3 | 2.3 |
| Lifitegrast | 4 | 1.9 | 1.9 |
| Etonogestrel | 10 | 1.6 | 1.6 |
| Levonorgestrel | 30 | 1.1 | 1.1 |
| Pomalidomide | 15 | 1.1 | 1.1 |
| Valbenazine | 3 | 0.9 | 0.9 |
| Tirzepatide | 18 | 0.8 | 0.8 |